Bemnifosbuvir Sulfate
Treatment of hepatitis C virus (HCV) infection
- CAS No.
- 2241337-84-6
- Indication Class
- Anti-infectives
- Patent Expiry
- To be assessed
- Therapeutic Area
- Antiviral / Hepatitis
- Labeled Purity
- 98%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- Candidate (In-research)
- Linked Intermediates
- Confirm per inquiry
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higherNo intermediate entries are on file for this API yet. You can still enquire by CAS number — we will route it to the supply side for manual sourcing.
Listing Logic · Why It's Worth Listing
An NS5B nucleotide analog with pangenotypic activity and a high resistance barrier, an important component of HCV combination and retreatment regimens.
Antiviral / Hepatitis · In research; suited to co-development
GMP/DMF-ready; supports regulatory filing and audit in target markets
Intermediates confirmed per inquiry
Data File Pack
Product Description
Bemnifosbuvir is an investigational drug under development, primarily investigated for the treatment of hepatitis C virus (HCV) infection. It belongs to the class of NS5B polymerase inhibitors, which work by inhibiting viral replication, thereby aiding in the control and management of the infection.
Supply source: Unibest · Bemnifosbuvir Sulfate, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.